Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
May 19, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation

NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and...
May 17, 2021 07:00 ET | Source: Fortress Biotech, Inc.

REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
May 16, 2021 16:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
May 10, 2021 06:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney...
April 07, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
March 31, 2021 16:15 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights

Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the...
March 22, 2021 09:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne

NEW YORK and SCOTTSDALE, Ariz., March 22, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner...
March 04, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
February 26, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...